Intellia Therapeutics (NTLA)
(Delayed Data from NSDQ)
$11.49 USD
-0.15 (-1.29%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $11.53 +0.04 (0.35%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Intellia Therapeutics, Inc. has a market cap of $1.21B, which represents its share price of $11.64 multiplied by its outstanding shares number of 103.58M. As a small-cap company, NTLA's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
NTLA 11.49 -0.15(-1.29%)
Will NTLA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NTLA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NTLA
BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
NTLA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Take the Zacks Approach to Beat the Markets: AngloGold Ashanti, Caterpillar & Hershey in Focus
Take the Zacks Approach to Beat the Markets: Amarin, Mogo, 3M in Focus
Intellia Gains 29.8% in a Month: How Should You Play the Stock?
Other News for NTLA
NTLA Awards Inducement Grant Amid Employment Expansion
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | NTLA ...
Intellia Therapeutics announces employee inducement grants
Commit To Buy Intellia Therapeutics At $10, Earn 28.5% Using Options